<DOC>
	<DOC>NCT00448058</DOC>
	<brief_summary>To evaluate the efficacy, safety, and tolerability of GSK372475 compared with placebo in the treatment of outpatient subjects with Major Depressive Disorder (MDD)</brief_summary>
	<brief_title>A Study Of New Medicine (GSK 372475) For The Treatment Of Depression</brief_title>
	<detailed_description>A Ten-Week, Multicenter, Randomized, Double-Blind, Placebo and Active-Controlled, Parallel-Group, Flexible-Dose Study Evaluating the Efficacy, Safety, and Tolerability of GSK372475 (1.5 mg/day to 2.0 mg/day) or Extended Release Venlafaxine XR (150 mg/day to 225 mg/day) Compared to Placebo in Adult Subjects Diagnosed with Major Depressive Disorder</detailed_description>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Venlafaxine Hydrochloride</mesh_term>
	<criteria>Major depressive episode (MDE) associated with Major Depressive Disorder (DSMIVTR criteria) Duration of current episode is at least 12 weeks duration and less than 2 years Symptoms of decreased energy, pleasure, and interest Female subjects who agree to use acceptable methods of birth control throughout the study Exclusion criteria: Current diagnosis of Panic Disorder, or symptoms of generalized anxiety or panic attacks that could interfere with their ability to complete the trial Symptoms of MDE better accounted for by another diagnosis Diagnosis of Bipolar, schizophrenia, other psychotic disorder(s), borderline or antisocial personality disorder, or dementia. Started psychotherapy within 3 months prior to the Screening Received electroconvulsive therapy or transcranial magnetic stimulation within 6 months prior to screening Received psychoactive drugs within 4 weeks of randomization Positive urine drug screen or positive blood alcohol Suicidal risk or has had any previous suicide attempt, a family history of suicide attempt Positive pregnancy test History of seizure disorder, myocardial infarction (&lt; 1yr), or unstable medical condition Failed to respond to an adequate course of pharmacotherapy of at least 2 different antidepressants</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>November 2011</verification_date>
	<keyword>Flexible-dose</keyword>
	<keyword>GSK372475</keyword>
	<keyword>MDD</keyword>
	<keyword>Venlafaxine XR</keyword>
	<keyword>Major Depressive Disorder</keyword>
</DOC>